We provide trade advice to complement the prevailing
expert consensus on Artelo Biosciences. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Artelo Biosciences income statement, its balance sheet, and the statement of cash flows. Potential Artelo Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Artelo Biosciences investors may use each financial statement separately, they are all related. The changes in Artelo Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Artelo Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Artelo Biosciences
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Artelo Biosciences performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Artelo Biosciences shares is the value that is considered the true value of the share. If
the intrinsic value of Artelo is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Artelo Biosciences. Please read more on our
fundamental analysis page.
Watch out for price decline
Please consider monitoring Artelo Biosciences on a daily basis if you are holding a position in it. Artelo Biosciences is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Artelo Biosciences stock to be traded above the $1 level to remain listed. If Artelo Biosciences stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How effective is Artelo Biosciences in utilizing its assets?
Artelo Biosciences reports assets on its Balance Sheet. It represents the amount of Artelo resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Artelo Biosciences aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Pharmaceuticals space. To get a better handle on how balance sheet or income statements item affect Artelo volatility, please check the breakdown of all its
fundamentals.
Are Artelo Biosciences Earnings Expected to grow?
The
future earnings power of Artelo Biosciences involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Artelo Biosciences factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Artelo Biosciences
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Artelo
expected earnings.
Artelo Biosciences Gross Profit
Artelo Biosciences Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Artelo Biosciences previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Artelo Biosciences Gross Profit growth over the last 10 years. Please check Artelo Biosciences'
gross profit and other
fundamental indicators for more details.
Detailed Perspective On Artelo Biosciences
The latest rise in Artelo Biosciences short term price appreciation could raise concerns from institutional investors as the firm is trading at a share price of
2.87 on very low momentum in volume. The company executives have successfully maneuvered the firm at convenient times to take advantage of all market conditions in
January. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.12. The above-average risk is mostly attributed to
market volatility and speculations regarding some of the upcoming earning calls from Artelo Biosciences partners.
| 2018 | 2019 | 2022 | 2023 (projected) |
Current Assets | 4.44 M | 2.34 M | 2.69 M | 2.9 M | Total Assets | 6.48 M | 4.38 M | 5.03 M | 5.43 M |
Asset Utilization
One of the ways to look at asset utilization of Artelo is to check how much profit was generated for every dollar of assets it reports. Artelo Biosciences shows a negative utilization of assets of -0.28 percent, losing $0.002775 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Artelo Biosciences shows how discouraging it operates for each dollar spent on its assets.
| Current Assets2.9 M | Assets Non Current2 M | Goodwill1.8 M |
| Current Assets | 2.9 Million | 42.99 |
| Assets Non Current | 2.02 Million | 29.97 |
| Goodwill | 1.82 Million | 27.05 |
How will Artelo institutional investors react to the next slide?
Standard deviation is down to 3.1. It may entail a possible volatility slide. Artelo Biosciences currently demonstrates below-average downside deviation. It has Information Ratio of 0.11 and Jensen Alpha of 0.34. However, we advise investors to further question Artelo Biosciences expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Artelo Biosciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Artelo Biosciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Takeaway on Artelo Biosciences Investment
Whereas other entities in the biotechnology industry are either recovering or due for a correction, Artelo Biosciences may not be performing as strong as the other in terms of long-term growth potentials. With an optimistic outlook on your 90 days horizon, it may be a good time to take up new shares of Artelo or increase your existing holdings in the Stock as it seems the potential growth has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Artelo Biosciences.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Artelo Biosciences. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com